Malaga Cove Capital’s BioLineRX BLRX Stock Holding History

Malaga Cove Capital’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-40	Closed	-$9K	–	152
2019 Q2	$9K	Hold	40	–	–	0.01%	158
2019 Q1	$10K	Hold	40	–	–	0.01%	162
2018 Q4	$11K	Sell	40 -42	-51%	-$20.2K	0.01%	162
2018 Q3	$55K	Hold	82	–	–	0.03%	155
2018 Q2	$44K	Hold	82	–	–	0.02%	152
2018 Q1	$43K	Buy	+82	New	+$50.2K	0.02%	146
2017 Q4	–	Sell	-73	Closed	-$51K	–	129
2017 Q3	$51K	Buy	73 +55	+306%	+$34.2K	0.03%	143
2017 Q2	$9K	Buy	+18	New	+$9.25K	0.01%	124

Other funds holding BLRX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

NFG

Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Malaga Cove Capital's BLRX Position: Q3 2019 in Review

Malaga Cove Capital sold out of BioLineRX (BLRX) in Q3 2019, closing a stake of 40 shares — an estimated $9K sold.

Malaga Cove Capital first reported a position in BLRX in Q2 2017 and held it in 8 quarters. The position peaked at $55K in Q3 2018. 15 funds tracked by Wall St. Rank hold BLRX as of Q3 2019.

Malaga Cove Capital reported no remaining BioLineRX position as of Q3 2019 after selling out during the quarter.
Malaga Cove Capital sold 40 BioLineRX shares in Q3 2019, an estimated $9K.
Malaga Cove Capital first reported a position in BioLineRX in Q2 2017 and held it in 8 quarters.
Malaga Cove Capital's BioLineRX position peaked at $55K in Q3 2018.
15 funds tracked by Wall St. Rank held BioLineRX as of Q3 2019.

Based on Malaga Cove Capital's 13F filing for Q3 2019, filed 31 Oct 2019.